ACRE

ACRE is an externally-managed (Ares) commercial mortgage REIT in the middle of a credit-driven shrink, not a growth story. Revenue has fallen four straight years — $107M (FY22) → $92.9M → $69.7M → $54.8M (-21.3% YoY) — because the loan book is being run off and impaired, not grown. The filing tells you why in plain terms: the company took a mixed-use Florida property via consensual foreclosure on an $82.9M defaulted senior mortgage (FY23), then a multi-building North Carolina office property via deed-in-lieu on a $68.6M defaulted loan (FY24), selling one building for just $5.3M in Dec 2025. That is office/CRE credit stress converting performing loans into hard-to-sell real-estate-owned. Cumulative pain shows up as a -$312M accumulated deficit and equity that has eroded every year to $510M.

The offsetting fact — and the reason this isn't an outright sell — is price. At $4.52 the stock trades at roughly 0.49x the $9.21 book value per share ($510M / 55.4M shares), and FY2025 losses narrowed dramatically to -$902K (a near-breakeven from -$35M the prior year) with operating cash flow still positive at $21.4M. Management reports compliance with all financial covenants, extended and upsized the Wells Fargo facility to $600M out to Feb 2028, and paid down the Secured Term Loan by $10M each quarter. A half-book discount already prices in meaningful further credit losses; if the remaining marks hold, there is asset-value cushion.